S&P 500   4,482.73
DOW   34,715.39
QQQ   361.72
S&P 500   4,482.73
DOW   34,715.39
QQQ   361.72
S&P 500   4,482.73
DOW   34,715.39
QQQ   361.72
S&P 500   4,482.73
DOW   34,715.39
QQQ   361.72
NASDAQ:CODX

Co-Diagnostics Stock Forecast, Price & News

$8.26
-0.14 (-1.67%)
(As of 01/20/2022 12:00 AM ET)
Add
Compare
Today's Range
$8.26
$8.63
50-Day Range
$8.12
$10.37
52-Week Range
$7.01
$20.69
Volume
277,539 shs
Average Volume
794,450 shs
Market Capitalization
$238.63 million
P/E Ratio
5.90
Dividend Yield
N/A
Beta
-3.32
30 days | 90 days | 365 days | Advanced Chart
Receive CODX News and Ratings via Email

Sign-up to receive the latest news and ratings for Co-Diagnostics and its competitors with MarketBeat's FREE daily newsletter.


Co-Diagnostics logo

About Co-Diagnostics

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight H. Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CODX
Fax
N/A
Employees
37
Year Founded
N/A

Sales & Book Value

Annual Sales
$74.55 million
Cash Flow
$1.47 per share
Book Value
$2.36 per share

Profitability

Net Income
$42.48 million
Pretax Margin
48.94%

Debt

Price-To-Earnings

Miscellaneous

Free Float
28,601,000
Market Cap
$238.63 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/11/2021
Today
1/21/2022
Next Earnings (Estimated)
3/24/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.78 out of 5 stars

Medical Sector

870th out of 1,418 stocks

Surgical & Medical Instruments Industry

88th out of 130 stocks

Analyst Opinion: 3.4Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -












Co-Diagnostics (NASDAQ:CODX) Frequently Asked Questions

Is Co-Diagnostics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Co-Diagnostics stock.
View analyst ratings for Co-Diagnostics
or view top-rated stocks.

How has Co-Diagnostics' stock been impacted by Coronavirus (COVID-19)?

Co-Diagnostics' stock was trading at $13.19 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CODX stock has decreased by 37.4% and is now trading at $8.26.
View which stocks have been most impacted by COVID-19
.

When is Co-Diagnostics' next earnings date?

Co-Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for Co-Diagnostics
.

How were Co-Diagnostics' earnings last quarter?

Co-Diagnostics, Inc. (NASDAQ:CODX) announced its quarterly earnings data on Thursday, November, 11th. The company reported $0.38 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.21 by $0.17. The business earned $30.10 million during the quarter, compared to analyst estimates of $24 million. Co-Diagnostics had a trailing twelve-month return on equity of 50.81% and a net margin of 40.11%. During the same period in the prior year, the company earned $0.53 EPS.
View Co-Diagnostics' earnings history
.

What guidance has Co-Diagnostics issued on next quarter's earnings?

Co-Diagnostics issued an update on its FY 2021 earnings guidance on Thursday, December, 9th. The company provided earnings per share (EPS) guidance of $1.070-$1.160 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.980. The company issued revenue guidance of $96 million-$100 million, compared to the consensus revenue estimate of $95.21 million.

What price target have analysts set for CODX?

4 Wall Street analysts have issued 1-year price objectives for Co-Diagnostics' stock. Their forecasts range from $14.00 to $15.00. On average, they anticipate Co-Diagnostics' stock price to reach $14.50 in the next year. This suggests a possible upside of 75.5% from the stock's current price.
View analysts' price targets for Co-Diagnostics
or view top-rated stocks among Wall Street analysts.

Who are Co-Diagnostics' key executives?

Co-Diagnostics' management team includes the following people:
  • Dwight Howard Egan, Chairman, President & Chief Executive Officer
  • Brian L. Brown, Chief Financial Officer & Secretary
  • Jesse Montgomery, Chief Scientific Officer
  • Reed L. Benson, General Counsel (LinkedIn Profile)

What other stocks do shareholders of Co-Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Moderna (MRNA), Vaxart (VXRT), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), iBio (IBIO), Advanced Micro Devices (AMD), Pfizer (PFE) and Johnson & Johnson (JNJ).

When did Co-Diagnostics IPO?

(CODX) raised $9 million in an IPO on Thursday, July 13th 2017. The company issued 1,300,000 shares at a price of $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities served as the underwriters for the IPO.

What is Co-Diagnostics' stock symbol?

Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX."

Who are Co-Diagnostics' major shareholders?

Co-Diagnostics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include UMA Financial Services Inc. (0.12%). Company insiders that own Co-Diagnostics stock include Dwight H Egan, Eugene Durenard, Reed L Benson and Richard S Serbin.
View institutional ownership trends for Co-Diagnostics
.

Which major investors are buying Co-Diagnostics stock?

CODX stock was bought by a variety of institutional investors in the last quarter, including UMA Financial Services Inc..
View insider buying and selling activity for Co-Diagnostics
or or view top insider-buying stocks.

How do I buy shares of Co-Diagnostics?

Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Co-Diagnostics' stock price today?

One share of CODX stock can currently be purchased for approximately $8.26.

How much money does Co-Diagnostics make?

Co-Diagnostics has a market capitalization of $238.63 million and generates $74.55 million in revenue each year. The company earns $42.48 million in net income (profit) each year or $1.40 on an earnings per share basis.

How many employees does Co-Diagnostics have?

Co-Diagnostics employs 37 workers across the globe.

What is Co-Diagnostics' official website?

The official website for Co-Diagnostics is www.codiagnostics.com.

Where are Co-Diagnostics' headquarters?

How can I contact Co-Diagnostics?

Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT, 84124. The company can be reached via phone at (801) 438-1036 or via email at [email protected].


This page was last updated on 1/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.